* Resistance to rifampicin and isoniazid only, Ofx-ofloxacin, Mfx-Moxifloxacin, Km-kanamycin, Am-Amikacin, Cm-capreomycin, Eto-ethionamide. Additional resistance to first and second-line anti-TB drugs
Understanding how M. tuberculosis survives during antibiotic treatment is necessary to rationally devise more effective tuberculosis chemotherapy regimens. Using genome-wide mutant fitness profiling a
There is limited evidence on the effect of DM co-morbidity in those undergoing treatment for MDR-TB. We report post-hoc analyses of participants from the STREAM Clinical Trial (Stage 1 and 2 combined)
